Our drug discovery capabilities utilize our proprietary databases and computer-based molecular design technologies, which we refer to collectively as Pentad™. Together with our proprietary assays and novel screening methods, Pentad enables us to efficiently identify, prioritize, characterize and optimize novel compounds designed to selectively target specific NNR subtypes to achieve a desired therapeutic effect and limit adverse side effects.

300-1000x reduction in laboratory effort 10-100x higher hit-rate in database mining the ability to quickly exploit new targets simultaneous optimization capability against multiple endpoints enhanced prediction accuracy